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Abstract: Systemic lupus erythematosus (SLE) is a chronic, multisystem, autoimmune 
disease that can affect any part of the human body including the eyes. Common blinding ocular 
manifestations include central retinal artery occlusion (CRAO), central retinal vein occlusion 
(CRVO), severe vaso-occlusive retinopathy, and optic nerve involvement. Antiphospholipid 
syndrome (APS) in lupus is usually associated with large vessel occlusions and needs prompt 
treatment with anticoagulant. We are reporting two cases of APS in SLE patients that presented 
with CRVO (case 1) and vaso-occlusive lupus retinopathy (case 2). Both cases were positive 
for antiphospholipid antibody (APA) and were treated with immunosuppression, anticoagulant, 
and laser treatment. Thus, screening for APA is vital in SLE patients with lupus retinopathy, 
as prompt treatment with anticoagulants is important to prevent further vascular thrombosis, 
which worsens the visual prognosis. 
Keywords: systemic lupus erythematosus, antiphospholipid antibody, central retinal vein 
occlusion, vaso-occlusive retinopathy
Introduction
Systemic lupus erythematosus (SLE) is a chronic, multisystem, autoimmune disease 
that can affect any part of the human body. Ocular manifestations in SLE are fairly 
common and should be taken seriously as they may lead to significant morbidity and 
visual deterioration. In addition to that, ocular manifestations could represent the 
disease activity of the lupus (especially in the presence of retinal signs) and serve as 
an indicator of adequacy of treatment in control of the disease.1 Common ocular signs 
that could lead to visual blinding complications include retinal involvement (central 
retinal artery occlusion [CRAO], central retinal vein occlusion [CRVO], severe vaso-
occlusive retinopathy, and retinal detachment) and optic nerve involvement (optic 
neuritis and ischemic optic neuropathy).2 Milder spectrum includes keratoconjunctivitis 
sicca, episcleritis, scleritis, and anterior uveitis.
Antiphospholipid antibodies (APA) have been recognized as a risk factor for 
complications in SLE and their clinical significance in ocular presentation have been 
associated with poorer prognosis.3 Clinicians will usually raise their suspicion of 
antiphospholipid syndrome (APS) in SLE patients if there is large vessel involvement 
such as CRAO or CRVO. We are reporting two cases of APS in SLE patients that 
presented with CRVO (case 1) and vaso-occlusive lupus retinopathy (case 2). 
Case series 
Case 1
A 19-year-old girl with known SLE for 3 years and was on maintenance oral pred-
nisolone 10 mg daily presented in the ophthalmology clinic at the Hospital Raja 
Permaisuri Bainun, Ipoh, Malaysia with sudden, painless loss of vision in the left 
eye of 1 day’s duration. There were no other manifestations of SLE or thrombotic 
events. Visual acuity was hand movement in the left eye with the presence of relative 
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afferent  pupillary defect (RAPD), and was 6/6 in the right 
eye. Anterior segment examinations of both eyes were 
unremarkable. Left fundoscopy showed extensive flame-
shaped intraretinal hemorrhages, dilated and tortuous retinal 
veins with swollen and hyperemic disc suggestive of CRVO 
(Figure 1). Right fundoscopy was unremarkable. Fundus 
fluorescein angiography (FFA) of the left eye revealed 
delayed venous filling and prolonged arteriovenous transit 
time with extensive capillary nonperfusion affecting 360° of 
peripheral retina with macular ischemia (Figure 2). FFA of 
the right eye was unremarkable. 
In view of the ocular vascular thrombotic event, she 
was screened for laboratory criteria for APS, which con-
sisted of lupus anticoagulant, anticardiolipin antibody, and 
β-2 glycoprotein-1 antibody. The screening revealed that 
the anticardiolipin antibody was positive at a moderate titer 
(IgG: 73.85 GPL units, IgM: 8.62 MPL units). 
She was given intravenous methylprednisolone 500 mg 
daily for 3 days followed by oral prednisolone 55 mg 
(1 mg/kg daily) for 2 weeks. Oral prednisolone was tapered 
down 10 mg every 2 weeks until 30 mg, and then further 
tapered down 5 mg weekly until maintenance of 5 mg daily. 
The patient was also treated with oral hydroxychloroquine 
(HCQ) 200 mg daily and oral warfarin 5 mg daily. She was 
reviewed regularly for international normalization ratio 
(INR) aiming at 2.0–3.0. She was planned for long-term treat-
ment of HCQ and oral anticoagulant. In view of the extensive 
capillary nonperfusion area in the left eye, laser panretinal 
photocoagulation (PRP) was given in three sessions with a 
total of 3,000 shots. 
Follow-up review at 16 weeks revealed her left visual 
acuity was 6/60. The left fundus showed pallor disc with 
resolving retinal hemorrhages with extensive sclerosed reti-
nal vessels (Figure 3). She is still on maintenance treatment 
with oral prednisolone 5 mg daily, oral HCQ 200 mg daily, 
and oral warfarin 5 mg daily.
Case 2 
A 16-year-old girl with known SLE and lupus nephritis for 
10 months, on maintenance oral prednisolone 20 mg daily, 
oral mycophenolate mofetil (MMF) 750 mg daily, and oral 
HCQ 200 mg twice daily. She had a history of deep vein 
thrombosis (DVT) 18 months ago. Her ultrasound Doppler 
showed thrombosis of the right external iliac and common 
femoral vein and was started on oral warfarin for 6 months 
duration. She presented to the ophthalmology clinic in Hos-
pital Raja Permaisuri Bainun, Ipoh, Malaysia with bilateral 
central scotomas of 4 days’ duration. The visual acuity was 
6/24 bilaterally with no RAPD. Anterior segment examina-
tions of both eyes were unremarkable. Fundoscopy showed 
multiple cotton wool spots, intraretinal hemorrhages, and 
macular edema bilaterally (Figure 4A and B). FFA showed 
perifoveal vasculitis with macular ischemia and capillary 
Figure 1 Left fundus showed extensive flame-shaped intraretinal hemorrhages, and 
dilated and tortuous veins with swollen and hyperemic disc at presentation.
Figure 2 Fundus fluorescein angiography of left fundus showed extensive capillary 
nonperfusion affecting 360° of peripheral retina (green arrows) with macular ischemia 
(yellow arrow).
Figure 3 Left fundus showed pale optic disc with resolving retinal hemorrhages and 
extensive sclerosed retinal vessels at week 16 of follow-up.
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Figure 4 Fundus findings at presentation for both eyes in case 2.
Note: Both fundus showed multiple cotton wool spots and intraretinal hemorrhages at presentation (A [right eye] and B [left eye]).
Figure 5 Fundus fluorescein angiography for both eyes in case 2.
Note: Fundus fluorescein angiography showed perifoveal vasculitis (red arrows) with macular ischemia (yellow arrows) and capillary nonperfusion (green arrows) at superior, 
temporal, and inferior parts of the retina in both eyes (A [right eye] and B [left eye]).
nonperfusion at superior, temporal, and inferior parts of the 
retina in both eyes (the left eye more severe than the right eye) 
(Figure 5A and B). These FFA findings were in keeping with 
vaso-occlusive lupus retinopathy. APA screening showed 
positive anticardiolipin antibody (IgG:12.6 GPL units) and 
lupus anticoagulant (ratio between 1.2 to 1.5).
She was given intravenous methylprednisolone 500 mg 
daily for 3 days followed by oral prednisolone 45 mg daily 
(1 mg/kg daily), then tapered down 10 mg every 2 weeks until 
maintenance of 10 mg daily. Oral anticoagulant (warfarin 
5 mg daily) was commenced. She was reviewed regularly 
for INR with the aim of 2.0 to 3.0. She was planned for 
long-term oral anticoagulant. In view of vaso-occlusive 
retinopathy at peripheral retina, laser PRP was given in both 
eyes at superior, temporal, and inferior parts of the retina in 
three sessions to prevent neovascularization.
At 12 weeks follow-up, her visual acuity was 6/12 in 
the right eye and 6/24 in the left eye with persistent central 
scotomas bilaterally. Both fundus showed resolving of cotton 
wool spots and intraretinal hemorrhages with the presence of 
hard exudate at the macular area (Figure 6A and B). She is 
still on maintenance treatment with oral prednisolone 10 mg 
daily, oral warfarin 5 mg daily, oral MMF 750 mg daily, and 
oral HCQ 200 mg twice daily. 
Discussion 
APS is an autoimmune disorder that frequently affects young 
women and leads to recurrent venous or arterial thrombosis 
and/or fetal loss. Diagnosis of APS requires one out of two 
clinical criteria (vascular thrombosis or pregnancy morbid-
ity) and one laboratory criteria that includes either lupus 
anticoagulant, anticardiolipin antibody in medium or high 
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Figure 6 Fundus findings at week 12 follow-up for both eyes in case 2.
Note: Both fundus showed resolving of cotton wool spots and intraretinal hemorrhages with presence of hard exudates at macular area at week 12 of follow-up (A [right 
eye] and B [left eye]).
titer, or anti-β2 glycoprotein-1 antibody. The presence of 
these autoantibodies causes imbalance to the hemostasis, 
which favors the prothrombotic state, thus leading to arterial 
and venous thrombosis, and is associated with more severe 
retinopathy and vascular occlusion.4 APA is often associ-
ated with a major vascular occlusion like CRVO or CRAO. 
CRVO cases are more likely than controls to have high anti-
cardiolipin antibody levels with an odds ratio of 6.26.5 The 
first patient presented with CRVO, which involved major 
vascular occlusion and illustrates a classical presentation 
of APS; thus, she was screened for APA, which turned out 
to be positive and was started on an anticoagulant with oral 
warfarin. Standard treatment for initial venous thrombotic 
event is early initiation with oral warfarin.6
Mild lupus retinopathy consists of cotton wool spots, 
retinal hemorrhages, and vascular tortuosity, where as severe 
lupus retinopathy consists of occlusion of retinal arterioles 
leading to retinal infarction, hence termed vaso-occlusive 
retinopathy or retinal vasculitis. Although the second 
patient only presented with features of vaso-occlusive lupus 
retinopathy, screening for APS was done in view of recent 
history of DVT, which turned out to be positive as well. 
Initial management of lupus retinopathy includes systemic 
immunosuppression (usually intravenous corticosteroids 
followed by oral steroid), which is then supplemented or 
replaced by other immunosuppressive agents. However, if 
APA is present, prompt use of anticoagulant is beneficial, 
as APA is linked to focal thrombosis.7 Therefore, screening 
for APS in the second patient prevented a delay in initiating 
the anticoagulant and worsening of her condition.
We have highlighted two cases of SLE whereby the first 
case with CRVO illustrates a classical presentation of APS 
and the second case with features of active vaso-occlusive 
lupus retinopathy. However, APS can be present in SLE 
regardless of the nature of retinopathy. Hence, screening 
for APS is useful, as prompt treatment with anticoagulants 
is important to prevent further vascular thrombosis and 
worsening visual prognosis. Although systemic steroids and 
antithrombotic agent were given in these cases, visual prog-
nosis was not good as a result of macular ischemia, leading to 
permanent visual disability. Nevertheless, the most important 
issue now is to prevent a similar condition in the fellow eye, 
therefore antiinflammatory and antithrombotic need to be 
given for a longer duration.  
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